New hope for tough blood cancers: experimental drug MGD024 enters human testing
NCT ID NCT05362773
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive the drug for up to a year, and doctors will check how the body responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SYSTEMIC MASTOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Colorado Blood Cancer Network
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
START - Midwest
Grand Rapids, Michigan, 49503, United States
-
South Austin Medical Center
Austin, Texas, 78704, United States
-
University of Maryland, Greenbaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can donor immune cells tame stem cell transplant risks?